Related Experiment Videos
Adverse drug reactions: keeping up to date
Jeffrey K Aronson1, Sheena Derry, Yoon K Loke
1University Department of Clinical Pharmacology, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK. jeffrey.aronson@clinpharm.ox.ac.uk
Fundamental & Clinical Pharmacology
|March 21, 2002
Summary
The vast literature on adverse drug reactions overwhelms non-specialists. More systematic reviews and quality-controlled anecdotal reports are needed for better understanding of drug safety.
Area of Science:
- Pharmacovigilance
- Drug Safety Research
- Medical Literature Analysis
Background:
- The volume of published literature on adverse drug reactions (ADRs) is extensive, with over 3000 new references annually in key serial publications.
- Pharmacotherapeutics journals publish a significant portion of ADR-related papers, but no single journal serves as a primary information hub.
Observation:
- Non-specialists primarily rely on secondary (reviews) and tertiary (critical summaries) literature for ADR information.
- Primary literature consists mainly of anecdotal reports (30%) and formal studies/randomized controlled trials (RCTs) (35%).
Findings:
- Anecdotal ADR reports vary widely in quality, suggesting a need for centralized, quality-controlled publications.
- While many RCTs are robust for efficacy, most are underpowered for detecting rare or subtle adverse drug reactions.
- Systematic reviews, crucial for synthesizing ADR evidence, constitute only 1.25% of cited publications, indicating a significant deficit.
Implications:
- Improving the quality and accessibility of ADR literature is essential for healthcare professionals and researchers.
- Developing dedicated platforms for high-quality anecdotal ADR reports could enhance drug safety surveillance.
- Increased generation and publication of systematic reviews on adverse drug reactions are urgently required to inform clinical practice and policy.